Abrégé

In one aspect, the present invention discloses a composition of forsythia suspensa component and an optional panax ginseng component that can be used safely, efficiently and consistently to achieve antiviral, antipyretic, anti-inflammatory and/or immunity boosting effects, including forsythin, forsythin derivatives, and the composition of forsythin and phillygenin for the prevention and treatment of diseases associated with human cytomegalovirus infection, such as simple human cytomegalovirus infection or for patients infected by human cytomegalovirus during prevention and treatment of cardiovascular and cerebrovascular diseases, tumors, bums or AIDS or during a process of organ transplantation or during the perinatal period. In another aspect, this application provides a process for preparing the composition of forsythia suspensa and panax ginseng components is simple, suitable for industrial production and easy to popularize.

Classes IPC  ?

• A61K 36/634 - Forsythia
• A61K 36/25 - Araliaceae (famille du ginseng), p. ex. lierre, aralia, schefflera ou tétrapanax
• A61K 31/724 - Cyclodextrines
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès

Abrégé

In one aspect, a composition of ginsenoside Rg3 and ginsenoside Rg5 and a preparation method thereof, as well as its application in manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effects, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effects. The composition has advantages in rapid action, less toxicity and side effects and is suitable for long-term use. In another aspect, a safe, highly efficient and stable drug, food or health product which can be obtained by a simple preparation process suitable for industrial production and which can be easily scaled up. In yet another aspect, a new type of components and production process for manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect.

Classes IPC  ?

• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 36/258 - Panax (ginseng)
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/26 - Psychostimulants, p. ex. nicotine, cocaïne
• A61P 35/00 - Agents anticancéreux
• A61P 39/00 - Agents protecteurs généraux ou antipoisons

Abrégé

The present invention provides a use of a phillyrin/phillygenin composition which targets and inhibits 3CLpro protein of COVID-19 virus, in preparation of an anti-coronavirus drug or a drug for treating a disease caused by the coronavirus, wherein the coronavirus is COVID-19 virus, and the disease caused by the coronavirus is COVID-19.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided is a composition with antiviral, antipyretic, anti-inflammatory and/or immunity-improving effects, which composition comprises a Forsythiae fructus component and can also comprise a Ginseng component, wherein the Forsythiae fructus component is phillyrin, a phillyrin derivative or a composition of phillyrin and phillygenin. The composition can be used for preparing drugs or food products or health-care products having corresponding functions, and can also be used for preparing anti-cytomegalovirus preparations.

Classes IPC  ?

• A61K 36/634 - Forsythia
• A61K 36/25 - Araliaceae (famille du ginseng), p. ex. lierre, aralia, schefflera ou tétrapanax
• A61P 31/12 - Antiviraux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 37/04 - Immunostimulants

Abrégé

A composition of ginsenoside Rg3 and ginsenoside Rg5, a preparation method therefor, and applications thereof in preparation of medications capable of improving drug resistance of immune, anti-tumor, and anti-tumor targeted medications, and reducing toxic and side reactions in radiotherapy and chemotherapy or resisting fatigue, and in preparation of food and health care products.

Classes IPC  ?

• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 36/904 - Stemonaceae (famille du stemona), p. ex. croomia
• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p. ex. bambou, blé ou canne à sucre
• A61K 36/8988 - Gastrodia
• A61K 36/898 - Orchidaceae (famille des orchidées)
• A61K 36/8968 - Ophiopogon (Ophiopogon japonicus)
• A61K 36/8966 - Fritillaria, p. ex. fritilaire
• A61K 36/8965 - Asparagus, p. ex. asperge ou asparagus
• A61K 36/8945 - Dioscorea, p. ex. igname, Dioscorea opposita ou Dioscorea alata
• A61K 36/725 - Ziziphus, p. ex. jujube
• A61K 36/57 - Magnoliaceae (famille du magnolia)
• A61K 36/258 - Panax (ginseng)
• A61P 37/04 - Immunostimulants
• A61P 35/00 - Agents anticancéreux
• A61P 39/00 - Agents protecteurs généraux ou antipoisons
• A61K 35/64 - Insectes, p. ex. abeilles, guêpes ou puces
• A61K 36/734 - Crataegus (aubépine)

Abrégé

Disclosed are phillyrin that targets the 3CLpro protein, which inhibits the COVID-19 virus, a derivative thereof, and the use of a composition of phillyrin and phylligenin in the preparation of a drug for resisting a coronavirus or treating a disease caused by a coronavirus, wherein the coronavirus is the COVID-19 virus and the disease caused by a coronavirus is COVID-19.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
• A61P 31/12 - Antiviraux

Abrégé

A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20(R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure. The above 20(R) ginsenoside Rg3 composition aqueous solution and the powder after lyophilizaton can be used to prepare injectable, oral administration and external use, and the bioactivity of these preparations is high, and with the actions of anti cancer, efficacy potentiation and toxicity attenuation effects of the combined chemical or radiation therapy of tumor, enhancement of human immune functions, improvement of human memory, anti fatigue, and detumescence, pain relieving.

Classes IPC  ?

• C07H 15/24 - Systèmes cycliques condensés comportant au moins trois cycles
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61P 35/00 - Agents anticancéreux